产品
编 号：F328736
分子式：C27H33NO7
分子量：483.55
分子式：C27H33NO7
分子量：483.55
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 343307-76-6
产品详情
生物活性：
L48H37 is an analog of Curcumin (HY-N0005) with improved chemical stability. L48H37 is a potent and specific myeloid differentiation protein 2 (MD2) inhibitor and inhibits the interaction and signaling transduction of LPS-TLR4/MD2. L48H37 is used for the research of sepsis or lung injury treatment.
体内研究：
L48H37 (intraperitoneal injection; 5?mg or 10?mg/kg; once daily; 11‐day?) inhibits H460 xenograft tumor growth and exhibits anti‐tumor activity in mice.Animal Model:5‐week‐old athymic BALB/cA nu/nu female mice (18‐22?g)
Dosage: 5?mg or 10?mg/kg
Administration:Intraperitoneal injection; once daily; 11‐day
Result:Reduced tumor wet weights as compared to vehicle control.Decreased the levels of p‐STAT3, and increased the levels of p‐EIF2α and ATF4 in vivo.Exhibited no significant structural changes in mice.
体外研究：
L48H37 inhibits LPS-induced inflammation, particularly TNF-α and IL-6 production and gene expression in mouse macrophages.L48H37 (0-20?μM; 24 hours) decreases the viability of A549 and H460 cells with IC50 values of 5.3?μM and 2.3?μM, respectively, which is more effective compared to curcumin in lung cancer cells. It shows a low cytotoxicity on normal human lung epithelial cells (BEAS-2B) with IC50?of 21?μM.L48H37 (1, 2, or 4?μM; 16 hours) dose‐dependently inhibited the expression of p‐Cdc2 and Cdc2, and increases the expression of p53. It also shows increased levels of cleaved poly (ADP‐ribosyl) polymerase (PARP) and reduced levels of anti‐apoptotic protein Bcl‐2 in H460 and A549 cells.L48H37 (4?μM; 16?hours) rapidly induces intracellular ROS levels dose-dependently as detected by increased DCF levels in H460 and A549 cells.
L48H37 is an analog of Curcumin (HY-N0005) with improved chemical stability. L48H37 is a potent and specific myeloid differentiation protein 2 (MD2) inhibitor and inhibits the interaction and signaling transduction of LPS-TLR4/MD2. L48H37 is used for the research of sepsis or lung injury treatment.
体内研究：
L48H37 (intraperitoneal injection; 5?mg or 10?mg/kg; once daily; 11‐day?) inhibits H460 xenograft tumor growth and exhibits anti‐tumor activity in mice.Animal Model:5‐week‐old athymic BALB/cA nu/nu female mice (18‐22?g)
Dosage: 5?mg or 10?mg/kg
Administration:Intraperitoneal injection; once daily; 11‐day
Result:Reduced tumor wet weights as compared to vehicle control.Decreased the levels of p‐STAT3, and increased the levels of p‐EIF2α and ATF4 in vivo.Exhibited no significant structural changes in mice.
体外研究：
L48H37 inhibits LPS-induced inflammation, particularly TNF-α and IL-6 production and gene expression in mouse macrophages.L48H37 (0-20?μM; 24 hours) decreases the viability of A549 and H460 cells with IC50 values of 5.3?μM and 2.3?μM, respectively, which is more effective compared to curcumin in lung cancer cells. It shows a low cytotoxicity on normal human lung epithelial cells (BEAS-2B) with IC50?of 21?μM.L48H37 (1, 2, or 4?μM; 16 hours) dose‐dependently inhibited the expression of p‐Cdc2 and Cdc2, and increases the expression of p53. It also shows increased levels of cleaved poly (ADP‐ribosyl) polymerase (PARP) and reduced levels of anti‐apoptotic protein Bcl‐2 in H460 and A549 cells.L48H37 (4?μM; 16?hours) rapidly induces intracellular ROS levels dose-dependently as detected by increased DCF levels in H460 and A549 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备